source
- Amylyx reports Phase 3 success for avexitide in post-bariatric hypoglycemiaAmylyx announced a late-stage success for avexitide, a GLP-1 receptor antagonist, in a Phase 3 trial targeting post-bariatric hypoglycemia. The trial results showed the drug achieved its primary e…
- Enveda reports promising Phase 1 data for oral drug that mimics exercise to preserve muscle during weight lossEnveda, a biotech based in Boulder, Colorado, announced Phase 1 results for its oral candidate ENV-308, a chemically engineered version of the metabolite lactate phenylalanine (lac-phe). The metabo…